IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.322
AS - Asia 5.683
EU - Europa 3.284
SA - Sud America 1.565
AF - Africa 273
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 28.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.059
SG - Singapore 2.572
BR - Brasile 1.249
CN - Cina 972
HK - Hong Kong 755
SE - Svezia 737
RU - Federazione Russa 601
FR - Francia 425
VN - Vietnam 372
IT - Italia 325
GB - Regno Unito 286
DE - Germania 265
IN - India 227
FI - Finlandia 126
CA - Canada 124
BD - Bangladesh 120
BE - Belgio 111
AR - Argentina 101
TR - Turchia 99
IQ - Iraq 78
ZA - Sudafrica 78
ID - Indonesia 76
MX - Messico 72
UA - Ucraina 67
JP - Giappone 59
CI - Costa d'Avorio 58
CO - Colombia 53
PK - Pakistan 49
VE - Venezuela 48
PL - Polonia 47
EC - Ecuador 45
ES - Italia 44
CZ - Repubblica Ceca 39
AT - Austria 30
NL - Olanda 30
SA - Arabia Saudita 30
UZ - Uzbekistan 29
MA - Marocco 25
AE - Emirati Arabi Uniti 23
MY - Malesia 22
IE - Irlanda 20
ET - Etiopia 19
PH - Filippine 19
CL - Cile 18
JO - Giordania 18
KE - Kenya 18
IL - Israele 17
LT - Lituania 17
NP - Nepal 17
BO - Bolivia 15
DZ - Algeria 15
IR - Iran 15
BG - Bulgaria 14
TN - Tunisia 14
EG - Egitto 13
PY - Paraguay 13
JM - Giamaica 12
RS - Serbia 11
CR - Costa Rica 10
KR - Corea 10
CH - Svizzera 9
HR - Croazia 9
KZ - Kazakistan 9
PE - Perù 9
PT - Portogallo 9
QA - Qatar 9
SY - Repubblica araba siriana 9
UY - Uruguay 9
AZ - Azerbaigian 8
BH - Bahrain 8
KW - Kuwait 8
RO - Romania 8
HN - Honduras 7
KG - Kirghizistan 7
PA - Panama 7
AL - Albania 6
DK - Danimarca 6
DO - Repubblica Dominicana 6
HU - Ungheria 6
LB - Libano 6
LY - Libia 6
TH - Thailandia 6
LV - Lettonia 5
NO - Norvegia 5
PS - Palestinian Territory 5
SR - Suriname 5
TT - Trinidad e Tobago 5
AO - Angola 4
AU - Australia 4
BB - Barbados 4
BY - Bielorussia 4
GE - Georgia 4
NI - Nicaragua 4
SN - Senegal 4
AM - Armenia 3
BW - Botswana 3
GR - Grecia 3
LU - Lussemburgo 3
MN - Mongolia 3
MT - Malta 3
Totale 28.071
Salva come PNG Salva come JPEG
Città #
Ashburn 2.107
Fairfield 2.052
Chandler 1.759
Singapore 1.440
Woodbridge 1.028
Seattle 916
Cambridge 905
San Jose 905
Houston 850
Hong Kong 748
Wilmington 652
Nyköping 564
Ann Arbor 395
Beijing 386
Dallas 303
Los Angeles 263
Lawrence 244
New York 243
Lauterbourg 234
Roxbury 229
Council Bluffs 170
Des Moines 149
Santa Clara 120
The Dalles 120
Ho Chi Minh City 113
Brussels 109
Paris 109
Columbus 107
Brooklyn 103
São Paulo 103
San Diego 99
Inglewood 91
Dearborn 89
Munich 87
Hanoi 85
London 80
Jacksonville 79
Helsinki 78
Moscow 74
Abidjan 58
Chicago 57
Pune 57
Tokyo 56
Denver 54
Frankfurt am Main 54
Atlanta 53
Bari 50
Boardman 49
Phoenix 49
San Francisco 49
Jakarta 45
Montreal 45
Orem 44
Warsaw 41
Nanjing 40
Buffalo 39
Rio de Janeiro 39
Washington 34
Chennai 33
Johannesburg 32
Baghdad 29
Turku 28
Brasília 26
Brno 26
Edinburgh 26
Mexico City 26
San Mateo 26
Tashkent 26
Ankara 25
Belo Horizonte 25
Falkenstein 25
Toronto 24
Da Nang 23
Falls Church 23
Guangzhou 23
Porto Alegre 23
Princeton 23
Stockholm 23
Boston 22
Dong Ket 22
Poplar 21
Vienna 21
Amsterdam 20
Dublin 20
Jinan 20
Ruvo Di Puglia 20
Shanghai 20
Istanbul 19
Mumbai 19
Rome 18
Addis Ababa 17
Campinas 17
Hefei 17
Monmouth Junction 17
Norwalk 17
Amman 16
Augusta 16
Düsseldorf 16
Manchester 16
Milan 16
Totale 20.023
Salva come PNG Salva come JPEG
Nome #
Molecularly targeted endocrine therapies for breast cancer 701
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 247
Angiogenesis in adenosquamous cancer of pancreas 218
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 202
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 200
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 191
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 181
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 179
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 178
Targeting angiogenesis in biliary tract cancers: An open option 166
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 165
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 165
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 161
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 160
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 160
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 159
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 158
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 156
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 156
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 155
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 155
Bone metastases in biliary cancers: A multicenter retrospective survey 155
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 154
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 154
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 153
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 152
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 151
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 151
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 150
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 149
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 148
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 147
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 147
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 147
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 146
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 144
Adjuvant therapy in colon cancer 143
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 142
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 142
Immunotherapeutic approaches for hepatocellular carcinoma 141
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 141
Molecular classifications of gastric cancers: Novel insights and possible future applications 140
Challenges and opportunities of MicroRNAs in lymphomas 140
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 139
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 139
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 139
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 139
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 139
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 137
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 137
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 136
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 136
Antineoplastic drug-induced bradyarrhythmias 136
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 135
Combined modality treatments in pancreatic cancer 135
Synthetic lethality to overcome cancer drug resistance 135
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 135
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 135
Target therapies in pancreatic carcinoma 135
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 135
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 134
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 134
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 134
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 133
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 133
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 133
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 133
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 132
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 132
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 132
Current status of targeted therapies in advanced gastric cancer 131
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 131
p53 as the main traffic controller of the cell signaling network 131
Actors on the scene: Immune cells in the myeloma niche 131
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 128
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 128
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 127
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 127
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 126
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 126
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 126
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 126
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 125
Oncosuppressor methylation: A possible key role in colon metastatic progression 125
Advances in EGFR-directed therapy in head and neck cancer 125
New molecular targets in bone metastases 125
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 125
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 124
Immunotherapy for colorectal cancer: where are we heading? 123
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 123
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 122
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 122
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 121
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 121
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 121
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 121
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 121
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 120
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and metaanalysis 119
Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers 118
Totale 14.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021383 0 0 0 0 0 0 0 0 0 0 264 119
2021/20222.191 154 209 40 77 159 149 110 133 142 111 224 683
2022/20233.687 399 514 291 360 316 413 111 474 541 25 203 40
2023/20241.168 84 216 80 101 123 322 19 66 9 28 10 110
2024/20254.546 95 82 359 207 153 513 381 418 162 222 734 1.220
2025/20269.282 1.489 407 596 826 1.278 530 1.132 306 1.050 776 892 0
Totale 28.733